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SUMMARY
Risk factors for invasive pneumococcal disease (IPD)
include young and old age, comorbidities (such as splenic
dysfunction, immunodeficiencies, chronic renal disease,
chronic heart or lung disease or cerebral spinal fluid
leak), crowded environments or poor socioeconomic con-
ditions. Universal use of the 7-valent pneumococcal con-
jugate (7vPncCRM) vaccine for infants and young children
has led to significant decreases in IPD in the vaccinated
population (direct protection), and there has also been a
decrease in the incidence of IPD among the nonvaccinated
population (indirect immunity; herd protection). While
7vPncCRM vaccine is administered universally to children
in USA, many countries of the European Union have
chosen to target children with comorbidities. This review
aims to highlight individual risk factors for IPD, describe
studies that evaluated pneumococcal conjugate vaccines in
at-risk groups and estimate the proportion of at-risk chil-
dren who may have been vaccinated in the European
Union since the 7vPncCRM vaccine was introduced,
using UK as an example. Although immunisation targeting
only children with comorbidities may achieve satisfactory
results for a few, many otherwise healthy children at risk
simply because of their age will be neglected, and herd
protection might not be established.
Keywords: Pneumococcal disease; risk factors; conjugate
vaccine; herd protection; immunisation programmes; USA;
UK; European Union; epidemiology; infant
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INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is a leading cause of
bacterial illnesses among children throughout the world,
responsible for invasive pneumococcal disease (IPD) (e.g.
meningitis, sepsis, bacteraemic pneumonia and bacteraemia)
and non-IPD (e.g. pneumonia, acute otitis media and sinusi-
tis). A 20-year (1980–1999) surveillance study conducted in
Nottingham, UK, for instance, found that the mean annual
incidence of IPD was 47.1 per 100,000 in infants younger
than 1 year (1). The expansion in recent years of pneumo-
coccal strains with diminished sensitivity to antibiotics has
complicated the treatment of IPD.
The 23-valent pneumococcal polysaccharide (23vPncPS)
vaccines, available since the 1980s, are licensed only for at-risk
individuals older than 2 years of age. With the advent of the
pneumococcal conjugate vaccine, the focus of disease manage-
ment for children below 2 years of age has shifted to preven-
tion. In spite of this advance in vaccinology, from the
polysaccharide to the conjugate vaccine, the concept that
pneumococcal vaccination would only be meant for at-risk
individuals has persisted in the minds of many public health
officials and practitioners.
Children younger than 2 years are one of the highest risk
groups for IPD; therefore, a 7-valent pneumococcal conjugate
(7vPncCRM) vaccine was developed that protects against the
important paediatric serotypes, 4, 6B, 9V, 14, 18C, 19F and
23F. Although young age is a major risk factor for IPD,
factors such as crowded living conditions and lower socio-
economic status may further increase the likelihood of devel-
oping pneumococcal disease (2) among otherwise healthy
children.
Two 7vPncCRM vaccine immunisation approaches have
been utilised to date: universal vaccination of all infants and
children, or vaccination targeted to certain vulnerable groups.
The USA adopted the former approach in August 2000, when
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REVIEW doi: 10.1111/j.1368-5031.2006.00858.xthe Advisory Committee on Immunization Practices (Centers
for Disease Control and Prevention) recommended vaccina-
tion for every infant and child younger than 2 years of age
and also recommended catch-up vaccination targeted for all
children 2–5 years of age with particular comorbidities (e.g.
sickle cell anaemia, splenic dysfunction, human immunodefi-
ciency virus (HIV) infection, chronic disease or an immuno-
compromising condition). Furthermore, US authorities
underscored that vaccination also should be considered for
all other children 2–5 years of age, with priority given to those
who are 2–3 years of age, those of African-American, Native
American or Alaskan native descent or those who attend out-
of-home childcare.
By contrast, the countries in the European Union have, to date,
adopted an approach targeted uniquely towards at-risk children.
The UK approach, for instance, is based on the January 2002
recommendations of the Joint Committee on Vaccination and
Immunisation, which were subsequently broadened in August
2004 to include additional comorbid conditions.
The goal of this article is to compare the two approaches:
universal vaccination of all infants and children and targeted
vaccination for certain at-risk groups. Specifically, we seek to
i) highlight the risk factors for IPD; and ii) describe studies that
have evaluated pneumococcal conjugate vaccines in at-risk
groups. Using UK as an example, we have tried to estimate the
proportion of at-risk infants and young children who may have
beenvaccinatedbetweentheintroductionof7vPncCRM vaccine
and the broadening of recommendations in August 2004.
RISK FACTORS FOR IPD
Predisposing factors, such as genetic factors, comorbidities or
other pathologies, may place an individual at risk of
developing IPD. Multiple genetic factors, for instance, are
almost certainly associated with an individual’s risk of IPD,
and some recognised phenotypic bases for risk include hypo-
gammaglobulinaemia, impaired opsonophagocytosis activity,
complement defects, or poor splenic clearance of intravascular
bacteria. Anatomic abnormalities (e.g. skull fracture/
cerebrospinal fluid leak, cochlear implant or congenital heart
disease), immunosuppressive therapy, bone marrow and solid
organ transplantation, chronic disease (pulmonary, neuro-
logical or hepatic), diabetes mellitus and renal conditions
(renal insufficiency or nephrotic syndrome) are other patho-
logies that increase risk (Table 1). The possibility of develop-
ing IPD is further complicated by the impact of
socioeconomic factors, perinatal factors and age – individuals
younger than 2 years or older than 65 years are particularly at
risk (Table 1) (3–10).
Nonetheless, most children hospitalised for IPD do not
belong to any recognised at-risk group. In a US surveillance
study, only 27% of hospitalised children had an underlying
condition (11), while Canadian, French, Spanish and Finnish
studies found that 23.2% (12), 16.7% (13), 10% (14) and
16% (15) of hospitalised children, respectively, had under-
lying conditions.
RISK-BASED RECOMMENDATIONS
THROUGHOUT EUROPE
In the European Union, the 7vPncCRM vaccine is licensed
for children from 2 months to 5 years of age. The national
recommendations, however, for the use of 7vPncCRM vac-
cine vary by country (Table 2). In Germany, Italy, Spain and
UK, for instance, the vaccine is currently only recommended
for high-risk individuals.
Table 1 Some risk factors for invasive pneumococcal disease (IPD)
Condition Incidence/Risk Reference
<2 years of age 34.3/100,000 USA population (3)
 65 years of age 41.6/100,000
Group day care (defined as spending
 4 h/week with  2 unrelated
children under adult supervision)
Two to threefold greater risk Vs. children not in group day care (4)
Low birth weight 2.6-fold greater risk Vs. normal birth weight (5)
Pre-term <38 weeks gestation 1.6-fold greater risk Vs. full term (5)
HIV-positive/AIDS 6100 cases/100,000 HIV-infected children <7 years (6)
11,300 cases/100,000 HIV-infected children <3 years (6)
Sickle-cell disease 5500–6500 cases/100,000 Children with sickle cell disease <5 years (6)
Socioeconomic factors Rate of IPD >threefold greater Canadian Aboriginals vs. Canadian
non-Aboriginals (7,8)
Pneumococcal bacteraemia and
pneumococcal meningitis rates are >fourfold greater
Alaskan Native children <5 years compared
with non-Alaskan
Native/non-Native American children (9)
IPD rates are 1.6-fold greater African-American children <2 years compared
with white children (10)
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vaccine vaccination is a three-dose primary series followed by
a booster dose in the second year of life. There are exceptions.
In UK, a three-dose primary series only is recommended (i.e.
no booster). In the Nordic countries and in Italy, the standard
paediatric vaccine regimen consists of a two-dose primary
series and a booster dose at about 12 months of age.
EFFICACY OF PNEUMOCOCCAL CONJUGATE
VACCINES IN AT-RISK GROUPS
Safety and immunogenicity studies in at-risk groups aim to
demonstrate that the immune response to a pneumococcal
conjugate vaccine is comparable to that seen in healthy sub-
jects, for which vaccine efficacy may have been demonstrated.
Some of the groups studied include children with sickle cell
disease, HIV-infected adults and children, adults with
Hodgkin’s disease or patients undergoing bone marrow
transplantation.
The immunologic response in children with sickle cell
disease is at least as substantial as that found in healthy
patients (16). Moreover, toddlers first immunised with a 9-
valent pneumococcal conjugate vaccine candidate followed by
a 23vPncPS vaccine had significantly higher antibody levels
for the serotypes tested than those vaccinated with the
23vPncPS vaccine alone (17). In children 2–6 years of age
with sickle cell disease who were previously given the
23vPncPS vaccine, higher antibody concentrations were
achieved with 7vPncCRM vaccine compared with no subse-
quent conjugate vaccine dose (18). It has also been shown that
one conjugate vaccine dose can prime toddlers for immuno-
logic memory, indicating that 7vPncCRM vaccine may confer
protection after one dose in children 2–5 years of age (19).
The immunogenicity of the 7vPncCRM vaccine has also
been demonstrated in HIV-infected adults (20) and children
(21,22), in adults with Hodgkin’s disease (23) and in patients
undergoing bone marrow transplantation (24). In one study
of HIV-infected infants, 7vPncCRM vaccine induced geo-
metric mean concentrations of serotype-specific serum anti-
body to levels >0.15 mg/ml in 95% of HIV-infected infants.
Although concentrations declined at 24 months, they
remained well above preimmunisation levels (25). In adults
with Hodgkin’s disease, priming with a 7vPncOMPC vaccine
candidate resulted in a significant increase in antibody con-
centration values after a subsequent dose of 23vPncPS vaccine
compared with nonprimed individuals (23). In patients
undergoing bone-marrow transplantation, post-transplantation
antibody responses after the first two vaccine doses were greater
among patients whose donors had initially received
7vPncCRM vaccine. By the third dose, >60% of patients
had antibody concentrations for each vaccine serotype
considered by these investigators to indicate protection
(i.e.  0.5 mg/ml) (24).
The immune response in individuals who are nonrespon-
ders to polysaccharide vaccine has also been shown to be
comparable to that seen in healthy subjects. In children and
adolescents with recurrent infections, two doses of
7vPncCRM vaccine resulted in a successful vaccination
(defined in this study as postvaccination titres of >1 mg/ml
for  5 of 7 serotypes) in 50% of patients; 80% responded to
 2 serotypes (26). In a separate study, 7vPncCRM vaccine
elicited only low responses in the recurrent infections patient
group; nevertheless, antibody levels were superior to those
observed with the 23vPncPS vaccine (27).
In contrast to these safety and immunogenicity studies,
there are a few efficacy studies in at-risk individuals. Studies
conducted to date show that 7vPncCRM vaccine is highly
efficacious in low birth weight and premature infants and is
protective for children of the Navajo Nation in North
America (5,28). Furthermore, in USA, where vaccination
with 7vPncCRM vaccine is recommended for every infant
and child younger than 2 years, and catch-up programmes are
targeted towards at-risk children younger than 5 years, the
racial disparity in IPD incidence, of children younger than 2
years, between African-Americans and whites has decreased
from 3.3-fold to 1.6-fold (8). Protection from IPD has also
been reported in children in the Republic of South Africa
with HIV infection (29).
ESTIMATED USE OF 7vPncCRM VACCINE IN
A T - R I S KC H I L D R E NI NU K
The number of distributed doses was obtained from UK Wyeth
sales records. It was assumed that all 7vPncCRM vaccine admi-
nistered in UK up to the issue of the broadened recommenda-
tions in August 2004 had been given to at-risk infants and
children younger than 2 years, and that they had only received,
on average, two doses. (For an unvaccinated English child aged
6–12 months, only two doses are necessary, while after the first
year only one dose is indicated). The estimates of the number of
infants and children in UK at risk for IPD January 2002 to
August 2004 were obtained by speaking with senior paediatric
specialists in each clinical area (gastro, haem, cardio, CF, liver,
renal, neonatal, HIV) and from their knowledge of the number
of patients in their own clinics and similar clinics throughout
UK, estimating numbers for UK. The numbers are likely to be
underestimates.
The estimated number of infants and young children in UK
who belonged to one of the groups identified to be at increased
risk for IPD during the period January 2002 to August 2004 is
summarised in Table 3. Excluding patients for whome exact
prevalence data were unavailable (i.e. diabetes, bone marrow
transplantation, primary immunodeficiency or splenectomy),
there were an estimated 4000 infants and young children in
UK who were eligible for 7vPncCRM vaccine in the first 2.5
years after its recommendation. Over that period, 14,800 doses
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certain that all the doses were used for this purpose (e.g. some
doses mayhavebeenadministeredtohealthy childrenor usedin
clinical trials), the number of doses distributed suggests that a
large proportion of eligible patients may have been immunised.
IMPACT OF 7vPncCRM VACCINE ON US
POPULATION
Clinical evaluation of 7vPncCRM vaccine for prevention of
IPD was obtained in a large-scale trial from October 1995 to
April 1999 involving 37,868 healthy infants in the Northern
California Kaiser Permanente (NCKP) population (30). In this
trial, the vaccine was 97% efficacious in the prevention of IPD
caused by 7vPncCRM vaccine serotypes in children vaccinated
with at least three doses, and 94% efficacious in children receiv-
ing at least one dose of the vaccine. Furthermore, the vaccine
was 89% effective in reducing all IPD, regardless of serotype. A
postlicensure analysis of 7vPncCRM vaccine that included the
entire NCKP population (vaccinated and nonvaccinated)
showed that from April 2002 to March 2003, no cases of
vaccine serotype disease were seen in children younger than 1
year, which compares favourably with a former incidence
ranging from 51.5 to 98.2 cases per 100,000 person-years in
the years before vaccine licensure. Additionally, there was no
evidenceofaconcomitantincreaseinIPDcausedbynonvaccine
serotypes (31), although close surveillance continues.
Pneumococcal conjugate vaccines reduce pneumococcal naso-
pharyngeal carriage among vaccinated individuals, which can
decrease the likelihood of transmission to unvaccinated persons,
with less risk of infection (referred to as indirect immunity or
herd protection). In a community-randomised, 7vPncCRM vac-
cine trial among Native Americans (28), nasopharyngeal carriage
was studied in family members living in the same household as a
c h i l dv a c c i n a t e dw i t ht h e7 v P n cCRM vaccine (32). Although
adult family members of vaccinated children had the same overall
pneumococcal nasopharyngeal rate as adult family members of
nonvaccinated children, adult family members of vaccinated
children had a significantly lower carriage rate of vaccine-type
pneumococci (p ¼ 0.02). Similarly, nonvaccinated children in
t h es a m eh o u s e h o l da sv a c c i n a t e dc hildren were less likely to carry
a vaccine-type strain than those living with nonvaccinated chil-
dren (relative risk ¼ 0.8; 95% confidence interval 0.7, 1.0) (32).
Recently, there has been further evidence that universal
immunisation of children younger than 2 years of age may
positively affect nonvaccinated populations. According to
Centers for Disease Control and Prevention’s Active
Bacterial Core Surveillance system, statistically significant
reductions in IPD incidence are observed in adults 20–39
years of age and in elderly adults >65 years of age (31,33).
THE FUTURE
Immunogenicity trials in individua l sw i t hH I V ,s i c k l ec e l ld i s e a s e
o rH o d g k i n ’ sd i s e a s e ,a sw e l la si nh a e m a t o p o i e t i cc e l lt r a n s p l a n t
recipients, show that the 7vPncCRM vaccine is both safe and
appropriately immunogenic; however, further research may be
needed in these and other high-risk groups to establish the
optimum schedule for the 7vPncCRM vaccine. Moreover,
several specific actions can be taken, both at the level of the
individual and in the general paediatric population, to improve
protection for at-risk groups. At the individual level, systemic and
mucosal immune responses to pneumococci might be enhanced
using an adjuvant, such as interleukin-12 (34) or LT-K63 (35),
or administering the vaccine by th em u c o s a lr o u t e .I na d d i t i o n ,
practical considerations should be implemented for children at
elevated individual risk of infection (i.e. anatomic defects, immu-
nosuppressive conditions or comorbidities), such as increasing
the number of outpatient visits for preventive care or improving
the provision of prophylactic antibiotics (36).
The diversity of recommendations for administration of
7vPncCRM vaccine to at-risk groups in countries of the
European Union is detailed in Table 2, and the lack of con-
sistency seems to reflect uncertainty among national authorities
as to who exactly is at risk. Clearly, the paediatric group at
highest risk for IPD includes all children younger than 2 years
of age; however, most of these children are not classified as at-
risk and therefore currently remain unprotected. As the identi-
fication of at-risk groups remains problematic, measures imple-
mented in the general paediatric population can benefit both
identified and unidentified at-risk groups.
An effective means of protecting at-risk individuals is to
reduce the chance of transmission by decreasing pneumococcal
nasopharyngeal carriage in the general paediatric population.
Thus, universal vaccination of children younger than 2 years
protects immunised children and, by means of herd protection,
Table 3 Estimated number of infants and young children in UK at
risk for invasive pneumococcal disease (IPD) during the period
January 2002 to August 2004
Condition Number
Coeliac disease 1400
Sickle cell disease 625
Chronic cardiac disease 500
Cystic fibrosis 400
Chronic liver disease 400
Pre-end stage renal failure 300
Chronic lung disease of prematurity 200
Nephrotic syndrome 140
End-stage renal failure 75
HIV infection 40*
Total 4080
*Estimate based on 400 infants and children in UK with HIV in total,
approximately 10% of whom are younger than 5 years of age. The number
of infants and young children in UK at risk for IPD due to diabetes, bone
marrow transplantation, primary immunodeficiency, or splenectomy could
not be estimated.
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with them. Extensive data support the safety, immunogenicity
and efficacy of 7vPncCRM vaccine against IPD in infants and
young children (30), and the most recent studies indicate
substantial indirect beneficial effects from universal vaccination
of all children younger than 2 years (28,31,33). In USA, where
a universal recommendation is established, postlicensure data
show that the incidence of disease has decreased on a nation-
wide level (31,33), among the vaccinated and the nonvacci-
nated, in small groups identified to be at greater risk, as well as
in members of the general population who do not belong to
one of these specific groups. This is in contrast with the
targeted approach used currently in the European Union,
where unrecognised at-risk individuals, as well as unvaccinated
members of the general population, remain vulnerable to
pneumococcal disease. Consequently, universal vaccination as
a consistent approach across the European Union may be
helpful to obtain the benefits of herd protection.
CONCLUSIONS
There are at least three arguments favouring universal vacci-
nation. First, herd protection (for unvaccinated infants, par-
ents and grandparents) cannot be achieved without broad
vaccine coverage. Second, it is impossible to identify most
of the infants who will be ‘at risk’. At the age when an infant
would receive 7vPncCRM vaccination series to ensure pro-
tective immunity (children 6–24 months of age), few children
can be identified as belonging to an at-risk group. Third, a
small percentage of hospitalised IPD cases will be avoided by
a targeted approach. Only about 5–10 percent of the overall
paediatric population has a comorbidity that health authori-
ties may recognise as a risk factor that is important enough for
IPD that 7vPncCRM vaccination is recommended.
Consequently, a targeted vaccination approach might lower
the rate of IPD among the overall paediatric population by no
more than a few percent (Figure 1).
The identification of high-risk individuals is often difficult,
and vaccination programmes that target only certain sub-
populations will miss individuals who would develop
pneumococcal disease. Based on the success of the US
experience, universal vaccination appears to be the most
effective in protecting all children, who are at risk simply
because of their young age.
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